Medtox files drug screening test with FDA :
This article was originally published in Clinica
Medtox Diagnostics, a subsidiary of Medtox Scientific, has submitted its PROFILE-ER drugs-of-abuse test to the US FDA for 510(k) marketing clearance. The product simultaneously detects nine of the most commonly used drugs-of-abuse - cocaine, amphetamines, cannabinoids, opiates, phencyclidine, benzodiazapine, barbiturate, tricyclic antidepressants and methadone. The test involves a one-step process and produces qualitative results in seven minutes, said St Paul, Minnesota-based Medtox. It will be targeted at hospital laboratories, emergency rooms and the urgent care market, allowing the end-user to perform an on-site screen for the drugs.